GRB2 associated regulator of MAPK1 subtype 2Genealiases: FAM59B · GAREML
Q-omics provides the consensus-scored GAREM2 profile across patient tissues and cancer cell-line models. GAREM2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GAREM2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, GAREM2 RNA expression shows 21,950 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where GAREM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAREM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAREM2 survival associations across molecular data types. GAREM2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAREM2 RNA expression–survival associations across cancer types. High GAREM2 expression shows unfavorable associations in ACC, MESO, UVM, SKCM and BLCA, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GAREM2 RNA expression.
This table summarizes GAREM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAREM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAREM2 shows lower tumor expression in COAD and higher tumor expression in KIRC, KIRP, HNSC, LUAD and LUSC. The KIRC box plot shows higher GAREM2 RNA expression in tumor versus normal tissue (log2 FC = +1.228, t-test p < 0.001).
This table shows molecular features associated with GAREM2 in patient tissues and cancer cell lines. In patient samples, GAREM2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GAREM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
